Çмú´ëȸ¾È³»»çÀüµî·ÏÃʷϵî·Ï¾È³»Ãʷϵî·Ï/°ü¸®¼÷¹Ú ¹× ±³Åë
ÀÚ·á Áß Ã·ºÎ ÆÄÀÏÀÌ ¿­¸®½ÃÁö ¾Ê´Â °æ¿ì¿¡´Â »ç¿ëÇϽô ÄÄÇ»ÅÍ ¼³Á¤À» ¾Æ·¡ÀÇ »çÇ×À¸·Î ¼ÂÆÃÇØÁֽʽÿÀ.
ºê¶ó¿ìÁ® »ó´ÜÀÇ 'µµ±¸' Ŭ¸¯ ->'ÀÎÅͳݿɼÇ'Ŭ¸¯ -> ÅÇÁß¿¡¼­ '°í±Þ'¼±Åà -> Ç׸ñÁß¿¡¼­ URLÀ» Ç×»ó UTF-8·Î º¸³¿(´Ù½Ã ½ÃÀÛÇØ¾ßÇÔ)¿¡ üũ¸¦ Áö¿ó´Ï´Ù.

* ¸ðµç ÀÏÁ¤ÀÇ Á¦¸ñÀº ÃßÈÄ º¯°æÀ̳ª Á¶Á¤ °¡´É ÇÔ

* ÀϽà : 2004³â 10¿ù 14ÀÏ(¸ñ) - 15ÀÏ(±Ý)

* Àå ¼Ò : ±×·£µåÈúư È£ÅÚ (È«Á¦µ¿ ¼ÒÀç)

2003 ³â 10 ¿ù 13 ÀÏ ( ¼ö )
  Á¦1ȸÀÇÀå Á¦2ȸÀÇÀå Á¦3ȸÀÇÀå Á¦4ȸÀÇÀå Á¦5ȸÀÇÀå Á¦6ȸÀÇÀå Á¦7ȸÀÇÀå ¿¡¸Þ¶öµåB
18:00-19:30 Satellite Symposium1
Çѹ̾àǰ
³ë¿µ¹«,½ÅÀͱÕ
Satellite Symposium2
´ë¿õÁ¦¾à
ÃÖÀ±½Ä,Á¤³²½Ä
           


2004 ³â 10 ¿ù 14 ÀÏ ( ¸ñ )
                                                                                                    * 07:30 - 08:30 Á¤±â ÆòÀÇ¿øÈ¸ (Çöó¹Ö°í, º»°ü 2Ãþ)
  Á¦1ȸÀÇÀå Á¦2ȸÀÇÀå Á¦3ȸÀÇÀå Á¦4ȸÀÇÀå Á¦5ȸÀÇÀå Á¦6ȸÀÇÀå Á¦7ȸÀÇÀå ¿¡¸Þ¶öµåB
08:30-10:00 ½ÉÆ÷Áö¿ò 1
-CAD-
¹Ú¿µ¹è,¹Ú½ÂÁ¤
½ÉÆ÷Áö¿ò 2
-Basic-
ÀÌ¸í¹¬,Á¶¸íÂù
½ÉÆ÷Áö¿ò 3
-HTN-
À̹æÇå,Àå°æ½Ä
Arrhythmia(1)

55-59 ¿¬±¸ºñ
ÃÖÀ±½Ä,½Åµ¿±¸


60-62 ¿¬±¸ºñ
È«¼øÁ¶,±è¿µÈÆ
Heart Failure

73-76 ¿¬±¸ºñ
±èÇö½Â,½Å±æÀÚ


77-80 ¿¬±¸ºñ
½ÉºÀ¼·,±èÀçÁß
Clinical Cardiology

91-95
ÀÌ¿ìÇü,À̰ÇÁÖ


96-99
¹®¾ð¼ö,À±È£Áß
Congenital and Pediatric Disease(1)

123-126
±èöȣ,¹Ú¿µÈ¯


127-130
ÀÌÈïÀç,ÁÖÂù¿õ
Æ÷½ºÅÍ
¹ßÇ¥(1)

(09:00 ~13:00)

1-80
10:00-10:30 ÈÞ   ½Ä
10:30-12:30
ÀþÀº
¿¬±¸ÀÚ»ó(1)

1-5
¹ÚÀÇÇö,·ù¿Õ¼º
ÀþÀº
¿¬±¸ÀÚ»ó(2)

6-10
Á¤³²½Ä,È«°æÇ¥
Clinical Award Session(1)

1-6
ÀÌ¿ø·Î,¹Ú¼º¿í
Clinical Award Session(2)

7-12
³ë¿µ¹«,¼ÛÀç°ü
Clinical Award Session(3)

13-18
±è¼º¼ø,ÀÓÅÂȯ
CAD(1)

100-103
°­Á¤Ã¤,±èÁ¾Áø


104-107
Á¶½Â¿¬,¾ÈÅÂÈÆ


108-112
½É¿øÈì,¹Ú½ÃÈÆ
½ÉÆ÷Áö¿ò 7
-¼Ò¾Æ-
ÀÌ»ó¹ü
12:30-14:00 Satellite Symposium 3
Çѱ¹³ë¹ÙƼ½º
ÀÌ¿ø·Î,ÀÓÁ¾À±
Satellite Symposium 4
Çѱ¹ MSD
ÀÌ ¿µ,¹èÁ¾È­
Satellite Symposium 5
º¸·ÉÁ¦¾à
ÃÖ±Ôº¸,ÃÖ°æÈÆ
Satellite Symposium 6
»ç³ëÇÇ-
½Åµ¥¶óº¸
¹ÚÀÇÇö,À强±¹
Satellite Symposium 7
Çѵ¶¾Æº¥Æ¼½º
±èÁ¾¼º,±Ç¿µÁÖ
   
14:00-15:30
CAD(2)

1-5
±Ç¿µÁÖ,¹Ú¼º¿í


6-9
±èÀçÇü,½Â±â¹è
CAD(3)

20-23
½ÅÀͱÕ,ʽÂÁ¦


24-27
¿Àµ¿ÁÖ,Àå¾ç¼ö
Basic(1)

38-41 ¿¬±¸ºñ
Á¶¸íÂù,±è¿µ±Ç


42-45 ¿¬±¸ºñ
ÀüÀº¼®,Á¤À͸ð
½ÉÆ÷Áö¿ò 4
-CHF-
¿Àº´Èñ,ÀÌ»óÈÆ
½ÉÆ÷Áö¿ò 5
-Imaging-
¹ÚÀçÇü,¹üÈñ½Â
½ÉÆ÷Áö¿ò 6
Atherosc-lerosis
¹ÚÁ¤ÀÇ,±èÈ¿¼ö
¼Ò¾Æ°ú
½ÉÆ÷Áö¿ò 8
-¼Ò¾Æ-
¹ÚÀμ÷,±è¿ëÁø
Æ÷½ºÅÍ
¹ßÇ¥(2)

(14:00 ~18:00)

81-160
15:30-16:00 ÈÞ   ½Ä
16:00-18:00
CAD(4)

10-14
¿Àµ¿ÁÖ,Á¤¿í¼º


15-19
±è¿µÁ¶,±è¼ø±æ
Aorta
/Vascular
/Others

28-32
ÃÖ¼®±¸,¼ÛÀç°ü


33-37
È«¼øÇ¥,±è¿øÈ£
Basic(2)

46-49 ¿¬±¸ºñ
±èö¹Î,¹Úâ±Ô


50-54 ¿¬±¸ºñ
½ÅÇöÈ£,°í±¤°ï
Arrhythmia(2)

63-68
±è¼º¼ø,±è±âºÀ


69-72
±èÀ¯È£,Á¶Á¤°ü
Diagnostic Imaging

81-85
À̵¿¼ö,ÃÖ¿¬Çö


86-90
ÀÓÅÂȯ,ÀÌÀçÅÂ
HTN

113-117 ¿¬±¸ºñ
¹ÚÁ¾ÈÆ,±èöȣ


118-122 ¿¬±¸ºñ
±èÀçÇü,¹ÚÁ¤¹è
Congenital and Pediatric Disease(2)

131-136
À±¿ë¼ö,¼º½ÃÂù


137-141
±è¼ºÈ£,±è³²¼ö
18:00-19:00 Satellite Symposium 8
¾Æ½ºÆ®¶ó-
Á¦³×Ä«
¿Àº´Èñ,±è±â½Ä
Satellite Symposium 9
GSK
¹Ú¿µ¹è,È«¼øÇ¥
Satellite Symposium 10
Çѱ¹È­ÀÌÀÚ
±è¼º¼ø,ÀÌÀç¿ì
         


2004 ³â 10¿ù 15ÀÏ ( ±Ý )
  Á¦1ȸÀÇÀå Á¦2ȸÀÇÀå Á¦3ȸÀÇÀå Á¦4ȸÀÇÀå Á¦5ȸÀÇÀå Á¦6ȸÀÇÀå Á¦7ȸÀÇÀå ¿¡¸Þ¶öµåB
08:00-09:00 Morning Conference
-CAD-
±è¿µÁ¶,½Â±â¹è
Morning Conference
-Echo-
¼Õ´ë¿ø,½É¿ÏÁÖ
Morning Conference
-CHF-
À¯±ÔÇü,ÀüÀº¼®
Morning Conference
-Arrhythmia-
³ëÅÂÈ£,±èÀ±³â
Morning Conference
-Imaging-
ÀÓÅÂȯ,¹®´ëÇõ
Morning Conference
-Basic-
¼­È«¼®,±è´ö°æ
Congenital and Pediatric Disease(3)

293-297 ¿¬±¸ºñ
±ÇÅÂÂù,°íÀç°ï


09:00-11:00
CAD(5)

142-147
ÀüÀçÀº,±ÇÇöö

148-153
È«ÅÃÁ¾,Çö¹Î¼ö

Echo(1)

167-171
¹Ú¼ºÈÆ,È«°æ¼ø

172-176
¹èÁ¾È­,Á¤Áø¿ø




CAD(6)

191-195
¹ÚÁ¤·Î,È«¸í±â

196-200
±è¼º±¸,ÀÌöȯ




Arrhythmia(3)

215-219
¿Àµ¿Áø,À̸í¿ë

220-224
ÃÖÀμ®,±èÁؼö




CAD(7)

238-242
¼ºÀÎȯ,ÇѱԷÏ

243-248
¾çÁÖ¿µ,Â÷µ¿ÈÆ




Basic(3)

262-266
±è´ö°æ,ÁÖ½ÂÀç

267-270 ¿¬±¸ºñ
¼­È«¼®,ÃÖµ¿ÁÖ




½ÉÆ÷Áö¿ò 11
-¼Ò¾Æ-
¸¶Àç¼÷,¼­µ¿¸¸
Æ÷½ºÅÍ
¹ßÇ¥(3)

(09:00 ~13:00)

161-238
11:00-11:20 ÈÞ   ½Ä
11:20-12:00 Ư   °­ (ÃÖ±Ôº¸)
- Arterial Stiffening with Age : Cause, Consequence, Measurement and Therapy -
12:00-13:30 ÃÑ   È¸ (Á¡ ½É)
13:30-15:00 ¿¬ ¼ö °­ ÁÂ
- Debate in the Management of Coronary Artery Diseases -
¹ÚÀÇÇö,Á¶½Â¿¬
½ÉÆ÷Áö¿ò 9
-Arrhythmia-
¼ÛÁ¤»ó,Á¶Á¤ÈÖ
½ÉÆ÷Áö¿ò 10
-Echo-
½Å¿µ¿ì,ÀüÀçÀº
Basic(4)

271-275
¹Ú¿µ¹è,¹é»óÈ«

276-279 ¿¬±¸ºñ
±èÈ¿¼ö,ÀÓµµ¼±

Congenital and Pediatric Disease(4)
298-301
ÃÖÁ¤¿¬,¼Õ¼¼Á¤

302-305
¼Õ⼺,³ëÁ¤ÀÏ

Æ÷½ºÅÍ
¹ßÇ¥(4)

(14:00 ~18:00)

239-306
15:00-15:30 ÈÞ   ½Ä
15:30-18:00
CAD(8)

154-159
¹Ú½ÂÁ¤,Á¤¸íÈ£

160-166
ÀÌ»óÈÆ,À±Á¤ÇÑ

Echo(2)

177-181
ÃÖ°æÈÆ,ÀüÈñ°æ

182-186
±è±Ç»ï,°­´öÇö

187-190
±è±â½Ä,¹Ú½Â¿ì



VHD

201-205
À庴ö,Àå°æ½Ä

206-210 ¿¬±¸ºñ
¾ÈÇõ,¹ÚÁ¾Ãá

211-214
¹ÚÇ¥¿ø,±èµ¿¼ö

CAD(9)

225-230
±èÁ¤Çö,±è¹«Çö

231-237 ¿¬±¸ºñ
ÀÌÀç¿ì,ÃÖµ¿ÁÖ

CAD(10)
249-254
¹Ú±Ý¼ö,±è¿µ´ë

255-261
È«°æÇ¥,ȲÈï°ï

Basic(5)

280-285
¹ÚÁ¤ÀÇ,ÇѱâÈÆ

286-292
±èÄ¡Á¤,±èµ¿¿î

ÀÇ·á±â»ç
¿¬¼ö°­ÁÂ


  


 



2004³â Ãß°èÇмú´ëȸ ÀÏÁ¤

* ÀϽà : 2004³â 10¿ù 14ÀÏ(¸ñ) - 15ÀÏ(±Ý)
* Àå ¼Ò : ±×·£µåÈúư È£ÅÚ

¡á Ư°­ [10¿ù 15ÀÏ 11: 20 - 12:20 ]
ÁÂÀå : ÃÖ±Ôº¸
Arterial stiffening with age : cause, consequence, measurement and therapy
 - Michael O'Rourke / St. Vincent's Hospital, Australia


¡á ¿¬¼ö°­Á [10¿ù 15ÀÏ 13:30 - 15:00 ]
Debate in the Management of Coronary Artery DiseasesÁÂÀå : ¹ÚÀÇÇö, Á¶½Â¿¬
  1. Thrombolysis vs. PCI for AMI 
  ±Þ¼º ½É±Ù°æ»öÁõ ȯÀÚ¿¡¼­ Ç÷Àü¿ëÇØÁ¦ Ä¡·áÀÇ ÀåÁ¡ - Àü³²ÀÇ´ë Á¤¸íÈ£  
  PCI is better - ¿¬¼¼¿øÁÖÀÇ´ë À±Á¤ÇÑ  
  2. PCI vs. CABG for 3 vessel disease 
  PCI is better - ¼­¿ïÀÇ´ë äÀÎÈ£  
  ´ÙÇ÷°üÁúȯ¿¡¼­ °ü»óµ¿¸Æ¿ìȸ¼ú - ¼º±Õ°üÀÇ´ë ÀÌ¿µÅ¹  
  3. Noninvasive stress test & medical tx vs. direct CAG & PCI 
  Noninvasive stress test and medical treatment is enough - °í·ÁÀÇ´ë ½É¿ÏÁÖ  
  Direct CAG and PCI is better - °¡Å縯ÀÇ´ë Á¤¿í¼º  


¡á ½ÉÆ÷Áö¿ò
[ 10¿ù 14ÀÏ 08:30 - 10:00 ]
1. CAD : New Approaches to Enhance the Result of PCIÁÂÀå : ¹Ú¿µ¹è, ¹Ú½ÂÁ¤
 1) °üµ¿¸Æ ¼ºÇü¼ú ÈÄ ÀçÇùÂøÀ» ¹æÁöÇÏ´Â ¾à¹°ÀÇ °³¹ß - ¼­¿ïÀÇ´ë ±èÈ¿¼ö
 2) Candidate polymers for DES - ÃæºÏÀÇ´ë ±èµ¿¿î
 3) Class of Drug -Eluting Stents and Systemic Drug Therapy : Clinical Trials - ¿¬¼¼ÀÇ´ë Àå¾ç¼ö
 4) Biological stent under development - °¡Å縯ÀÇ´ë ½Â±â¹è
  Discussion

2. ±âÃÊ¿¬±¸ : Oxidative Stress and Cardiovascular Diseases ÁÂÀå : ÀÌ¸í¹¬, Á¶¸íÂù
 1) Overview of oxidative stress and antioxidant defence system - Àü³²Ä¡´ë ÀÌÅÂÈÆ
 2) Atherosclerosis and Oxidative Stress - ¿ï»êÀÇ´ë ÇѱâÈÆ
 3) Heart failure, redox alterations and endothelial dysfunction - µ¿¾ÆÀÇ´ë ±è¿µ´ë
 4) Ç×»êÈ­Á¦ »ç¿ë¿¡ ´ëÇÑ ÃÖ±Ù Àӻ󿬱¸ °á°ú - °í·ÁÀÇ´ë ¼­È«¼®

3. Hypertension : Ç÷¾ÐÁ¶ÀýÀÇ ÃÖÀûÈ­ ÁÂÀå : À̹æÇå, Àå°æ½Ä
 1) °íÇ÷¾Ð; Ç÷¾ÐÀ» ¾îµð±îÁö ³·Ãâ °ÍÀΰ¡?
  J-curve´Â ¾ø´Ù. - Áß¾ÓÀÇ´ë ±èÄ¡Á¤
  J-curve°¡ ÀÖ´Ù. - ¼º±Õ°üÀÇ´ë ¹ÚÁ¤¹è
  Rebuttal ¹× ÅäÀÇ
 2) °­¾ÐÁ¦ÀÇ ¼±ÅÃ- Ç¥ÀûÀå±âº¸È£¿Í ¾àÁ¦ÀÇ ¼±ÅÃ
  Æ¯Á¤¾àÁ¦°¡ ´õ È¿°úÀûÀÌ´Ù. - °í·ÁÀÇ´ë ¹Úâ±Ô
   °íÇ÷¾ÐÄ¡·á½Ã Ç¥ÀûÀå±â º¸È£¸¦ À§Çؼ­ ƯÁ¤ÇÑ ¾àÁ¦ÀÇ ¼±ÅÃÀÌ ÇÊ¿äÇѰ¡ - ÇÊ¿ä¾ø´Ù. - ¼­¿ïÀÇ´ë ±èöȣ
  Rebuttal ¹× ÅäÀÇ
 3) ±Ù°ÅÁß½ÉÀÇÇаú °íÇ÷¾Ð Áø·áÁöħ - °æºÏÀÇ´ë 伺ö
 4) Á¾ÇÕÅä·Ð


[ 10¿ù 14ÀÏ 14:00 - 15:30 ]


4. CHF : Management of HF According to Its EtiologyÁÂÀå : ¿Àº´Èñ, ÀÌ»óÈÆ
 1) ÃÖ±Ù Àӻ󿬱¸¿¡ ±âÃÊÇÑ ¸¸¼º ½ÉºÎÀüÀÇ Ä¡·á - ¼­¿ïÀÇ´ë ¿Àº´Èñ
 2) °íÇ÷¾Ð¼º ½ÉºÎÀüÀÇ ¿¹¹æ°ú Ä¡·á - ÇѸ²ÀÇ´ë À¯±ÔÇü
 3) Stem Cell Therapy for Ischemic Cardiomyopathy - ¼­¿ïÀÇ´ë °­ÇöÀç
 4) Degenerative valvular heart disease: how to evaluate the reversibility? - °¡Å縯ÀÇ´ë À±È£Áß
 5) Àü°Ý¼º ½É±Ù¿° ȯÀÚ¿¡¼­ ¼øÈ¯ º¸Á¶ÀåÄ¡ Ä¡·á - ¼º±Õ°üÀÇ´ë ÀüÀº¼®

5. Imaging : Recent Progress of Myocardial ImagingÁÂÀå : ¹ÚÀçÇü, ¹üÈñ½Â
 1) ½É±Ù PETÀ» ÀÌ¿ëÇÑ °üµ¿¸ÆÇ÷·ù¿Í Ç÷·ù¿¹ºñ´É ÃøÁ¤ - ¼­¿ïÀÇ´ë À̵¿¼ö
 2) Coronary CT Angiography - ¼º±Õ°üÀÇ´ë ÃÖ¿¬Çö
 3) MR assessment of myocardial viability - ¿ï»êÀÇ´ë ÀÓÅÂȯ
 4) Cardiovascular molecular imaging - Àü³²ÀÇ´ë ¹ÎÁ¤ÁØ
 Discussion

6. Atherosclerosis & Vascular Biology : Recent Progress in Atherosclerosis & Vascular    BiologyÁÂÀå : ¹ÚÁ¤ÀÇ, ±èÈ¿¼ö
 1) Potential Roles of Circulating Vascular Progenitor Cells in Progression and Remodeling or Atheroscleotic Lesions - Masataka Sata / University of Tokyo, Japan
 2) Therapeutic Angiogenesis Using HGF (hepatocyte growth factor) to Treat Ischemic Cardiovascular Diseas - Hironori Nakagami / Osaka University, Japan
 3) Recent Progress in Atherosclerosis and Vascular Biology - Richard T. Lee / Brigham & Women's Hospital, U.S.A


[ 10¿ù 14ÀÏ 10:30 - 12:30 ]
7. ¼Ò¾Æ : Valvular Heart DiseaseÁÂÀå : ÀÌ»ó¹ü
 ¿¬ÀÚ : Christian P Brizard / Royal Children's Hospital, Australia
 1) Mitral valve surgery in pediatric patient, state of art
 2) Ross procedure in pediatric patient


[ 10¿ù 14ÀÏ 14:00 - 15:30 ]
8. ¼Ò¾Æ : Valvular Diseases of the Left Heart in ChildrenÁÂÀå : ¹ÚÀμ÷, ±è¿ëÁø
 1) The Left Heart Valves: Normal Anatomy, Physiology - ¼­¿ïÀÇ´ë ¹èÀºÁ¤
 2) ¼±Ãµ¼º ÁÂ½É ÆÇ¸·Áúȯ: ÇüÅÂ, º´Å»ý¸® ¹× Áø´Ü - ¿ø±¤ÀÇ´ë À±Çâ¼®
 3) Aortic Valve Repair and Its Long Term Results - ¼­¿ïÀÇ´ë ±è¿õÇÑ
 4) ¼±Ãµ¼º ½Â¸ðÆÇ¸· Áúȯ¿¡¼­ÀÇ ÆÇ¸·¼ºÇü¼ú - ¼º±Õ°üÀÇ´ë Àüű¹
 5) Left Heart Valve Replacements: Surgical Technique, Choice of Valve, Postoperative Management and Long Term Results - ¿¬¼¼ÀÇ´ë ¹Ú¿µÈ¯


[ 10¿ù 15ÀÏ 13:30 - 15:00 ]
9. ºÎÁ¤¸Æ : Sudden Death from Inheritant Arrhythmia SyndromesÁÂÀå : ¼ÛÁ¤»ó, Á¶Á¤ÈÖ
 1) ºÎÁ¤¸Æ¾ß±â¼º ¿ì½É½ÇÀÌÇü¼ºÁõ - °æºÏÀÇ´ë Á¶¿ë±Ù
 2) ºÎ¸£°¡´Ù ÁõÈıºÀÇ ÃÖ½ÅÁö°ß - ¿ï»êÀÇ´ë ³²±âº´
 3) Long QT syndrome - °í½ÅÀÇ´ë Â÷ÅÂÁØ

10. ½ÉÃÊÀ½ÆÄ : Emerging Echocardiographic TechniquesÁÂÀå : ½Å¿µ¿ì, ÀüÀçÀº
 1) Real-Time Three-Dimensional Echocardiography in Clinical Practice - ÇѸ²ÀÇ´ë È«°æ¼ø
 2) ½Ç½Ã°£ 3Â÷¿ø ½ÉÃÊÀ½ÆÄ°Ë»çÀÇ ÀÓ»óÀû¿ë ¹× ¿¬±¸ - ÀÎÇÏÀÇ´ë ±Ç ÁØ
 3) Tissue Doppler Imaging - ¼º±Õ°üÀÇ´ë ¹Ú½Â¿ì
 4) Role of TDI in the assessment of cardiac resynchronization therapy - Cheuk-Man Yu / Chinese University, Hong Kong




[ 10¿ù 15ÀÏ 09:00 - 11:00 ]
11. ¼Ò¾Æ : Fontan OperationÁÂÀå : ¸¶Àç¼÷, ¼­µ¿¸¸
 1) Hemodynamics and systolic and diastolic function in single ventricle - ºÎ»êÀÇ´ë ÀÌÇüµÎ
 2) Preoperative evaluation of Fontan candidates - ¼º±Õ°üÀÇ´ë °­À̼®
 3) Surgical management of patients with single ventricle - ¼¼Á¾º´¿ø ÀÌâÇÏ
 4) Medical and interventional management of failing Fontan circulation - ¿ï»êÀÇ´ë ±è¿µÈÖ
 5) Surgical management of failing Fontan operation - ¿ï»êÀÇ´ë ¹ÚÁ¤ÁØ
 6) Long-term outcome of Fontan operation - ¼¼Á¾º´¿ø ÀÌÀ翵




¡á Morning Conference
[ 10¿ù 15ÀÏ 08:00 - 09:00 ]
1. CAD : Drug Eluting StentÁÂÀå : ±è¿µÁ¶, ½Â±â¹è
 1) General Review and Considerations in Rec-World - ÀÌÈ­ÀÇ´ë ¹Ú½ÃÈÆ
 2) Oral antiplatelet regimen in the era of DES - ÇѸ²ÀÇ´ë ÇѱԷÏ
 3) Subacute Stent Thrombosis with Drug Eluting Stent - ¼­¿ïÀÇ´ë ¿¬ÅÂÁø
 4) ¾à¹°¿ëÃâÇü½ºÅÙÆ®¿¡¼­ Ç÷°ü³»ÃÊÀ½ÆÄ °Ë»çÀÇ ÀÌ¿ë - µ¿¾ÆÀÇ´ë ±è¹«Çö

2. ½ÉÃÊÀ½ÆÄ : Doppler Hemodynamics in Routine Clinical Practice: Strength and Pitfall

ÁÂÀå : ¼Õ´ë¿ø, ½É¿ÏÁÖ

 1) DopplerÀ» ÀÌ¿ëÇÑ ½Â¸ðÆÇ ÁúȯÀÇ ÁßÁõµµ Æò°¡ - ¿ï»êÀÇ´ë °­´öÇö
 2) Doppler quantitation in aortic stenosis and regurgitation À̹ÌÁö ( 1 | 2 | 3 | 4 ) - ¼­¿ïÀÇ´ë Á¶ÁÖÈñ
 3) Assessment of regional myocardial function using TDI - Cheuk-Man Yu / Chinese University, Hong Kong

3. CHF : Basic Mechanism of Heart FailureÁÂÀå : À¯±ÔÇü, ÀüÀº¼®
 1) E-C coupling and calcium handling proteins: implications for heart failure À̹ÌÁö ( 1 | 2 ) - ´Ü±¹ÀÇ´ë ±è¿µ±Ç
 2) ½ÉºÎÀü¿¡¼­ º£Å¸¼ö¿ëü ½ÅÈ£Àü´Þ°æ·ÎÀÇ º¯È­¿Í ÀÓ»óÀû ÀÇÀÇ - ¼­¿ïÀÇ´ë ÃÖµ¿ÁÖ
 3) ºó¸Æ À¯¹ß¼º ½É±ÙÁõ(Tachycardia-induced Cardiomyopathy) - ÇѸ²ÀÇ´ë ÇѼº¿ì

4. ºÎÁ¤¸Æ : New Concept of Arrhythmogenesis and Treatment of Clinical Arrhythmia

ÁÂÀå : ³ëÅÂÈ£, ±èÀ±³â

 1) Nerve Sprouting and Arrhythmogenic Gene Expression in a Mouse Model of Myocardial Imfarction - °¡Å縯ÀÇ´ë ¿À¿ë¼®
 2) Optical Mapping of VF and VF Ablation - °í·ÁÀÇ´ë ¹ÚÈñ³²
 3) Clinical Review of Cardiac Resynchronization Therapy for Heart Failure - C Hwang / U.S.A

5. ½ÉÀ念»ó : From Image to PracticeÁÂÀå : ÀÓÅÂȯ, ¹®´ëÇõ
 1) From CT to Practice : Multidetector CT - ¿¬¼¼ÀÇ´ë ÃÖº´¿í
 2) Cardiac Imaging : From MRI to Practice - ¼¼Á¾º´¿ø ±è¾ç¹Î
 3) °üµ¿¸ÆÁúȯ¿¡¼­ ½É±Ù°ü·ù½ºÄµÀÇ ÀÀ¿ë - °æºÏÀÇ´ë ÀÌÀçÅÂ

6. ±âÃÊ ¿¬±¸ : Introduction to Molecular Cardiology and Its Application

ÁÂÀå : ¼­È«¼®, ±è´ö°æ

 1) DNA, RNA, ´Ü¹éÁúÀ» ÀÌ¿ëÇÑ ½ÉÇ÷°üÁúȯÀÇ ¿¬±¸¿Í Ä¡·á - ¿¬¼¼ÀÇ´ë ¹ÚÇö¿µ
 2) ¼¼Æ÷¹è¾ç°ú À̽ÄÀ» ÀÌ¿ëÇÑ ½ÉÇ÷°üÁúȯÀÇ ¿¬±¸¿Í Ä¡·á - ÃæºÏÀÇ´ë Ȳ°æ±¹
 3) ½ÉÇ÷°üÁúȯ¿¡¼­ÀÇ À¯ÀüÀÚ Ä¡·á - ¼º±Õ°üÀÇ´ë ÃÖÁøÈ£



¡á Satellite Symposium
[ 10¿ù 13ÀÏ 18:00 - 19:30 ]
1. į½Ç»ê ¾Ï·ÎµðÇÉÀÇ ÀÏ»ó ¹× »ï»ó ±¹³» ÀÓ»ó°á°úÁÂÀå : ³ë¿µ¹«, ½ÅÀͱÕ
 1) į½Ç»ê ¾Ï·ÎµðÇÉ(¾Æ¸ðµðÇÉTM)ÀÇ ¾àµ¿ÇÐ/¾à·ÂÇÐÀû Ư¼º ¹× ³»¾à¼º - °¡ÃµÀÇ´ë ¹ÚÁö¿µ
 2) º»Å¼º °íÇ÷¾ÐȯÀÚ¿¡¼­ į½Ç»ê ¾Ï·ÎµðÇÉ(Amlodipine Camsylate, AmodipinTM)ÀÇ À¯È¿¼º ¹× ¾ÈÀü¼º - °¡Å縯ÀÇ´ë Á¤¿í¼º

2. °íÇ÷¾Ð Ä¡·á¿¡¼­ »õ·Î¿î ARBÀÇ ¿ªÇÒÁÂÀå : ÃÖÀ±½Ä, Á¤³²½Ä
 1) Optimal use of angiotensin receptor antagonists - Hans R. Brunner / University of Lausanne, Switzerland
 2) ±Ù°ÅÁß½ÉÀÇÇаú °íÇ÷¾ÐÁø·áÁöħ - °æºÏÀÇ´ë 伺ö



[ 10¿ù 14ÀÏ 12:30 - 14:00 ]
3. Treatment of High Risk Hypertension Patients & VALUE ResultsÁÂÀå : ÀÌ¿ø·Î, ÀÓÁ¾À±
 1) °íÀ§Ç豺 °íÇ÷¾Ð ȯÀÚ¿¡ ´ëÇÑ ÀÓ»óÀû Á¢±Ù - ¿¬¼¼ÀÇ´ë ÇÏÁ¾¿ø

 2) VALUE trial-its implication beyond BP control - ¼­¿ïÀÇ´ë ÃÖµ¿ÁÖ

4. New Therapeutic Strategies to Optimize Treatment of Hypertension and Dyslipidemia

ÁÂÀå : ÀÌ ¿µ, ¹èÁ¾È­

 1) Current practice in treatment of isolated systolic hypertension - °í·ÁÀÇ´ë ¹Úâ±Ô
 2) Optimizing lipid management by dual inhibition - Claude R. Benedict / University of Texas Medical School, U.S.A

5. Arterial Stiffening, SNS, and CCB in HypertensionÁÂÀå : ÃÖ±Ôº¸, ÃÖ°æÈÆ
 1) Vascular characteristics and antihypertensive therapy in hypertension - Michael O'Rourke / St. Vincent's Hospital, Australia
 2) Effects of cilnidipine on sympathetic nervous system and arterial stiffness in essential hypertension - ¼º±Õ°ü
ÀÇ´ë ¹ÚÁ¤¹è

6. ARBs and Cardioprotection; Potential Role of Irbesartan in the Management of Diastolic Heart    Failure ÁÂÀå : ¹ÚÀÇÇö, À强±¹
 Management of Diastolic Heart Failure Patients with Irbesartan - Henry Krum / Monash University, Australia

7. New Frontiers in Blockade of the Renin-angiotensin System - Ccardiovascular and    Cerebrovascular ChallengesÁÂÀå : ±èÁ¾¼º,±Ç¿µÁÖ

 Looking for a Better Antihypertensive Treatment to Effectively Prevent Cardiovascular Disease, Focus on Eprosartan - Alejandro de la Sierra / University of Barcelona, Spain

 Cardiovascular Risk Reduction: The Importance of ACE Inhibition - Greg Conner / University of Sydney, Australia



[ 10¿ù 14ÀÏ 18:00 - 19:00 ]
8. ½ÉºÎÀü ½Å°æÈ£¸£¸ó ¾ïÁ¦Á¦ Ä¡·áÀÇ ÃֽŠ¿¬±¸ °á°úÁÂÀå : ¿Àº´Èñ, ±è±â½Ä
 1) ¸¸¼º ½ÉºÎÀüȯÀÚ¿¡¼­ ¾ÈÁö¿ÀÅٽмö¿ëü Â÷´ÜÁ¦ÀÇ ÃÖ±Ù Àӻ󿬱¸°á°ú - ÇѸ²ÀÇ´ë À¯±ÔÇü
 2) º£Å¸Â÷´ÜÁ¦ ¹× ±âŸ ½Å°æÈ£¸£¸ó¾ïÁ¦Á¦ - ¿ï»êÀÇ´ë ±èÀçÁß

9. Additional Benefits of Anti-hypertensive DrugsÁÂÀå : ¹Ú¿µ¹è, È«¼øÇ¥
 1) Pulse wave velocity effects of Lacidipine treatment in hypertensive patients - °¡Å縯ÀÇ´ë ¹é»óÈ«
 2) Additional benefits of Telmisartan - °í·ÁÀÇ´ë ¼­È«¼®

10. A Sea Change in CV TreatmentÁÂÀå : ±è¼º¼ø, ÀÌÀç¿ì
 1) Çѱ¹ÀÎÀÇ ½ÉÇ÷°ü Áúȯ ¹ß»ý ¿¹Ãø ¸ðÇü °³¹ß ¿¬±¸ - ¿¬¼¼ÀÇ´ë Áö¼±ÇÏ
 2) Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? - Treating to New Targets (TNT) Study
- David Douglas Waters / University of California, U.S.A
 3) The role of salts in physicochemical, pharmacologic and pharmacokinetic properties - Andrew M Lipczynski / Pfizer Global Research £¦ Development, U.K | Peter A. Meredith / University of Glasgow, UK